NCT00515203 - Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

August 31, 2009

Conditions

Idiopathic Thrombocytopenic PurpuraThrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Interventions

DRUG

Placebo

Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.

DRUG

AMG 531

Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.